IDEXX Laboratories (IDXX) Expected to Announce Earnings on Monday

Key Points

• IDEXX Laboratories is set to announce its Q2 2025 earnings on August 4th, with analysts predicting an earnings per share (EPS) of $3.28 and revenue of $1.06 billion.
• The company recently reported Q1 earnings of $2.96 EPS, exceeding analyst expectations, and its revenue has shown a 3.6% year-over-year increase.
• IDEXX's market capitalization stands at $45.45 billion, with recent price targets set between $540 and $625 by various analysts.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Monday, August 4th. Analysts expect the company to announce earnings of $3.28 per share and revenue of $1.06 billion for the quarter. IDEXX Laboratories has set its FY 2025 guidance at 11.930-12.430 EPS.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The firm had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. During the same period in the previous year, the business posted $2.71 earnings per share. The business's revenue for the quarter was up 3.6% on a year-over-year basis. On average, analysts expect IDEXX Laboratories to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.

IDEXX Laboratories Stock Performance

Shares of IDXX stock traded down $0.98 during trading hours on Wednesday, reaching $572.09. The company had a trading volume of 704,523 shares, compared to its average volume of 712,086. The business has a fifty day moving average price of $528.61 and a 200-day moving average price of $469.18. IDEXX Laboratories has a one year low of $356.14 and a one year high of $579.47. The firm has a market cap of $46.01 billion, a PE ratio of 52.87, a price-to-earnings-growth ratio of 4.03 and a beta of 1.54. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.16.

Analysts Set New Price Targets

Several brokerages recently issued reports on IDXX. Stifel Nicolaus boosted their target price on shares of IDEXX Laboratories from $510.00 to $540.00 and gave the company a "hold" rating in a research report on Wednesday, July 2nd. Morgan Stanley upped their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Leerink Partners upped their target price on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, July 17th. Wall Street Zen upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Saturday, July 12th. Finally, Jefferies Financial Group began coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They set a "buy" rating and a $625.00 target price for the company. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and a consensus price target of $557.88.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director M Anne Szostak sold 1,260 shares of the firm's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the transaction, the director owned 1,801 shares of the company's stock, valued at $922,724.34. This trade represents a 41.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.98% of the company's stock.

Institutional Trading of IDEXX Laboratories

A hedge fund recently raised its stake in IDEXX Laboratories stock. Empowered Funds LLC grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 6.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,538 shares of the company's stock after purchasing an additional 95 shares during the quarter. Empowered Funds LLC's holdings in IDEXX Laboratories were worth $646,000 as of its most recent SEC filing. 87.84% of the stock is owned by institutional investors.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.